13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001856083
Total reported value
$6.9B
$6.9B
65 檔
13.8%
In Q2 2025, Deep Track Capital, LP's U.S. equity holdings reached a combined market value of $6.9B, distributed across 65 disclosed stock positions.
Deep Track Capital, LP executed strategic sector rebalancing during Q2 2025, establishing 7 new positions while fully exiting 11 holdings and trimming 20 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | GH | Guardant Health Inc | Stock-Healthcare | 7.09% | +2.37% | -21.93% | |
| 2 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 6.20% | +0.15% | +7.17% | |
| 3 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 5.75% | — | +8.20% | |
| 4 | DVAX | Dynavax Technologies CORP | Stock-Other | 5.66% | — | — | |
| 5 | INSM | Insmed Inc | Stock-Healthcare | 5.65% | — | +586.95% | |
| 6 | AKRO | Akero Therapeutics Inc | Stock-Other | 5.21% | — | -5.22% | |
| 7 | IMVT | Immunovant Inc | Stock-Other | 4.87% | +0.56% | — | |
| 8 | OCUL | Ocular Therapeutix Inc | Stock-Other | 4.25% | +0.09% | — | |
| 9 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 3.89% | -2.98% | EXIT | |
| 10 | CYTK | Cytokinetics Inc | Stock-Healthcare | 3.87% | -0.61% | +18.74% | |
| 11 | GPCR | Structure Therapeutics Inc | Stock-Other | 3.41% | +0.33% | +25.22% | |
| 12 | ETNBGBP | 89bio Inc | Stock-Other | 2.99% | — | +1.97% | |
| 13 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 2.68% | -0.55% | — | |
| 14 | VRDN | Viridian Therapeutics Inc | Stock-Other | 2.41% | +0.51% | — | |
| 15 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 2.27% | -0.76% | +17.90% | |
| 16 | PCVX | Vaxcyte Inc | Stock-Other | 2.24% | -0.44% | +186.67% | |
| 17 | NRIX | Nurix Therapeutics Inc | Stock-Other | 2.22% | +1.12% | +10.27% | |
| 18 | GERN | Geron CORP | Stock-Other | 1.94% | -0.77% | EXIT | |
| 19 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 1.81% | -0.81% | +27.53% | |
| 20 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 1.57% | — | — | |
| 21 | MAZE | Maze Therapeutics Inc | Stock-Other | 1.55% | -0.08% | +20.79% | |
| 22 | ANIP | Ani Pharmaceuticals Inc | Stock-Other | 1.46% | -0.75% | EXIT | |
| 23 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 1.36% | — | +35.00% | |
| 24 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 1.33% | — | -5.28% | |
| 25 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.31% | +0.92% | — | |
| 26 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 1.25% | -1.02% | EXIT | |
| 27 | AUTL | Autolus Therapeutics PLC | Stock-Other | 1.23% | — | -5.59% | |
| 28 | ✓ | Stock-Other | 1.00% | — | — | ||
| 29 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 0.90% | -0.92% | EXIT | |
| 30 | TECX | Tectonic Therapeutic Inc | Stock-Other | 0.89% | — | — | |
| 31 | ABVX | Abivax Sa-adr | Stock-Other | 0.85% | — | -2.77% | |
| 32 | JBIO | Jade Biosciences Inc | Stock-Other | 0.80% | — | — | |
| 33 | MBX | Mbx Biosciences Inc | Stock-Other | 0.80% | +0.05% | -27.50% | |
| 34 | CMPS | Compass Pathways PLC | Stock-Other | 0.79% | +1.40% | -0.32% | |
| 35 | GHRS | GH Research PLC | Stock-Other | 0.78% | +1.30% | NEW | |
| 36 | BCAX | Bicara Therapeutics Inc | Stock-Other | 0.72% | +0.45% | +21.33% | |
| 37 | ORKA | Oruka Therapeutics Inc | Stock-Other | 0.69% | +1.04% | +32.82% | |
| 38 | ✓ | Engene Holdings Inc | Stock-Other | 0.53% | -0.49% | EXIT | |
| 39 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 0.52% | — | — | |
| 40 | UPB | Upstream Bio Inc | Stock-Other | 0.51% | — | -37.26% | |
| 41 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 0.47% | +0.27% | NEW | |
| 42 | ✓ | Merus N V | Stock-Other | 0.46% | — | — | |
| 43 | HELP | Cybin Inc | Stock-Other | 0.41% | -0.10% | EXIT | |
| 44 | CDTX | Cidara Therapeutics Inc | Stock-Other | 0.39% | — | — | |
| 45 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 0.39% | — | -21.11% | |
| 46 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 0.27% | — | +56.87% | |
| 47 | ✓ | Crescent Biopharma Inc. | Stock-Other | 0.23% | -0.14% | EXIT | |
| 48 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 0.21% | -2.05% | EXIT | |
| 49 | NVAX | Novavax Inc | Stock-Healthcare | 0.20% | — | -34.23% | |
| 50 | IVVD | Invivyd Inc | Stock-Other | 0.20% | — | -11.69% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | INSM | Insmed Inc | +5% | +586.95% | Add |
| 2 | AXSM | Axsome Therapeutics Inc | +2.7% | NEW | New buy |
| 3 | IONS | Ionis Pharmaceuticals Inc | +1.7% | +7.17% | Add |
| 4 | PCVX | Vaxcyte Inc | +1.3% | +186.67% | Add |
| 5 | GPCR | Structure Therapeutics Inc | +1.1% | +25.22% | Add |
| 6 | PTGX | Protagonist Therapeutics Inc | +1.1% | +8.20% | Add |
| 7 | AKRO | Akero Therapeutics Inc | +1% | -5.22% | Trim |
| 8 | OCUL | Ocular Therapeutix Inc | +0.9% | — | Unchanged |
| 9 | ETNBGBP | 89bio Inc | +0.8% | +1.97% | Add |
| 10 | JBIO | Jade Biosciences Inc | +0.8% | NEW | New buy |
| 11 | ✓ | Merus N V | +0.5% | NEW | New buy |
| 12 | IMCR | Immunocore Holdings Plc-adr | +0.5% | +27.53% | Add |
| 13 | 430 | Terns Pharmaceuticals Inc | +0.4% | +34.40% | Add |
| 14 | CDTX | Cidara Therapeutics Inc | +0.4% | NEW | New buy |
| 15 | MAZE | Maze Therapeutics Inc | +0.4% | +20.79% | Add |
| 16 | APLSUSD | Apellis Pharmaceuticals Inc | +0.4% | +40.00% | Add |
| 17 | AUTL | Autolus Therapeutics PLC | +0.3% | -5.59% | Trim |
| 18 | XENE | Xenon Pharmaceuticals Inc | +0.3% | +35.00% | Add |
| 19 | ✓ | Crescent Biopharma Inc. | +0.2% | NEW | New buy |
| 20 | ORKA | Oruka Therapeutics Inc | +0.2% | +32.82% | Add |
| 21 | 260 | Centessa Pharmaceuticals-adr | +0.2% | NEW | New buy |
| 22 | RAPT | Rapt Therapeutics Inc | +0.2% | NEW | New buy |
| 23 | CLDX | Celldex Therapeutics Inc | +0.1% | — | Unchanged |
| 24 | ABVX | Abivax Sa-adr | +0.1% | -2.77% | Trim |
| 25 | NRIX | Nurix Therapeutics Inc | +0.1% | +10.27% | Add |
| 26 | HELP | Cybin Inc | +0.1% | — | Unchanged |
| 27 | TECX | Tectonic Therapeutic Inc | +0.1% | — | Unchanged |
| 28 | MBX | Mbx Biosciences Inc | +0.1% | -27.50% | Trim |
| 29 | GHRS | GH Research PLC | +0.1% | — | Unchanged |
| 30 | VRDN | Viridian Therapeutics Inc | +0.1% | — | Unchanged |
| 31 | BCYC | Bicycle Therapeutics Plc-adr | +0.1% | +56.87% | Add |
| 32 | UPB | Upstream Bio Inc | +0.1% | -37.26% | Trim |
| 33 | OLMA | Olema Pharmaceuticals Inc | +0.1% | — | Unchanged |
| 34 | BRD1EUR | Mind Medicine Mindmed Inc | +0.1% | — | Unchanged |
| 35 | ✓ | 0% | — | Unchanged | |
| 36 | CNTX | Context Therapeutics Inc | 0% | — | Unchanged |
| 37 | IVVD | Invivyd Inc | 0% | -11.69% | Trim |
| 38 | ✓ | Ikena Oncology Inc | 0% | — | Unchanged |
| 39 | SYRE | Spyre Therapeutics Inc | — | — | Unchanged |
| 40 | CLYM | Climb Bio Inc | — | — | Unchanged |
| 41 | RARE | Ultragenyx Pharmaceutical In | 0% | — | Unchanged |
| 42 | ALGS | Aligos Therapeutics Inc | 0% | — | Unchanged |
| 43 | INO | Inovio Pharmaceuticals Inc | 0% | -36.48% | Trim |
| 44 | CMPS | Compass Pathways PLC | 0% | -0.32% | Trim |
| 45 | GERN | Geron CORP | 0% | +12.64% | Add |
| 46 | NGNE | Neurogene Inc | 0% | EXIT | Sold out |
| 47 | ALLKGUSD | Allakos Inc | -0.1% | EXIT | Sold out |
| 48 | XNCR | Xencor Inc | -0.1% | — | Unchanged |
| 49 | DNTH | Dianthus Therapeutics Inc | -0.1% | -5.28% | Trim |
| 50 | OKUR | Onkure Therapeutics Inc-a | -0.1% | -65.55% | Trim |
According to official SEC Form 13F filings, Deep Track Capital, LP reported a total U.S. public equity portfolio value of $6.9B across 65 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including GH, IONS, PTGX) accounted for 13.8% of total reported equity market value during Q2 2025.
Top New Position Initiated
AXSM
市值: $83.7M
Top Position Liquidated / Trimmed
ITCIEUR
前期市值: $263.8M
During Q2 2025, Deep Track Capital, LP's top holdings by market value included GH (7.1%)、IONS (6.2%)、PTGX (5.8%). The largest single position, GH, represented 7.1% of total portfolio value.
In Q2 2025, Deep Track Capital, LP made 56 total portfolio adjustments, initiating 7 new buys, adding to 18 positions, trimming 20 holdings, and fully liquidating 11 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.